Free Newsletter
TX institutions partner with Merck on chlamydia vax
Researchers in Texas have signed on to work on a new chlamydia vaccine for Merck.
Merck will provide funding for the work at the University of Texas San Antonio and the UT Health Science Center in San Antonio, which will tackle the sexually-transmitted bacteria Chlamydia trachomatis.
"Chlamydia is the most common sexually-transmitted disease caused by a bacterium, and the number of cases is on the rise," immununology professor Bernard Arulanandam says. "While many researchers have tried to develop a chlamydia vaccine, none has been successful. We hope to change that."
In an animal study, the researchers have found that recombinant C trachomatis agents can fight the bacteria while protecting the female's reproductive ability.
- read the report from the San Antonio Business Journal
Related Article:
New chlamydia vaccine being tested
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: